Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study

Lignende værker

• Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
  af: Kai-ni Shen, et al.
  Udgivet: (2024-03-01)
• Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients
  af: Huan Xie, et al.
  Udgivet: (2026-06-01)
• Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study
  af: Wanting Zheng, et al.
  Udgivet: (2026-12-01)
• Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
  af: Andrew Spencer, et al.
  Udgivet: (2018-12-01)
• REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
  af: EQ Crusoe, et al.
  Udgivet: (2024-10-01)